Cell and gene therapies promise breakthrough outcomes but many stumble at launch.
In this panel led by Beghou Partner Vishal Singal, leaders from Novartis, Orca Bio, BioMarin, and Beghou shared real-world lessons on what drives CGT success, from cross-functional collaboration to adapting models and tech to meet unique commercialization challenges.
Here's the full video:
Key topics covered:
- What’s working and not working: Why do some CGTs succeed while others stall? What are key lessons learned and "watch outs" leading into a CGT launch?
- Clinical to commercial: How and when do you engage with other functions - especially commercial - during development? Which functions are most critical to successful launches, and how does cross-functional collaboration evolve from development to launch?
- Tailoring the model: In CGT, strategies around partnerships, access, cost, and supply chain vary based on factors like cell vs. gene, rare vs. broad indications, and single-asset vs. portfolio. What are one or two areas you see as most critical to adapt?
- Operationalizing for complexity: Do you think that the data, tech, and workflows are evolving at the pace science is moving to meet the unique demands of CGT launches?
- Future Outlook: How do we overcome CGT challenges? What innovations will we need to bring about to reduce complexity and achieve more success?